Palatin Technologies, Inc. (0KF3)

Overview

Palatin Technologies, Inc. is a pioneering biopharmaceutical enterprise based in Cranbury, New Jersey, primarily engaged in the development of innovative receptor-specific therapeutics for the treatment of diverse diseases. With a foundation laid in 1986, the company has dedicated its efforts to harnessing the potential of targeted receptor interactions, focusing on conditions that lack effective treatments. Its mission is underscored by a commitment to addressing unmet medical needs through groundbreaking scientific discoveries and advancements.

Products and Services

Palatin Technologies has made significant strides in therapeutics, spearheading a variety of treatments across different phases of clinical trials. These efforts are mainly centered around melanocortin receptor (MCr) agonists, showcasing a targeted approach to treatment development.

• Vyleesi: As the company's flagship product, Vyleesi holds the distinction of being a melanocortin receptor agonist designed explicitly for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This revolutionary drug provides a novel treatment option, addressing an important area of women's health that has historically lacked focused therapeutic attention.
• Oral PL8177: This selective MC1r agonist peptide is in Phase 2 clinical trials targeting the treatment of inflammatory bowel diseases (IBD). PL8177 showcases the company's broader application of melanocortin receptor science, expanding into the realm of inflammatory diseases with the potential to offer new hope to patients afflicted by conditions such as Crohn's disease and ulcerative colitis.
• PL9643: Targeting the treatment of anti-inflammatory ocular indications such as dry eye disease, PL9643 is a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r. Currently in Phase 3 clinical trial, this product represents the company's foray into ophthalmology, applying its melanocortin expertise to address common but challenging ocular conditions.
• Diabetic Retinopathy Treatments: Palatin Technologies is also engaging in the development of melanocortin peptides aimed at treating diabetic retinopathy, a serious eye condition that can affect individuals with diabetes. This initiative reflects the company's commitment to leveraging its technology for broader therapeutic applications, particularly in addressing complications associated with chronic diseases.
• PL8177 for Ulcerative Colitis: An oral peptide formulation of PL8177 has entered Phase 2 clinical trials for the treatment of ulcerative colitis. This advance reinforces the company's ongoing efforts to explore versatile therapeutic potentials of its melanocortin agonist technology, particularly in the area of gastrointestinal diseases.